EP0992512B1 - Reduced cortisol conjugate - Google Patents

Reduced cortisol conjugate Download PDF

Info

Publication number
EP0992512B1
EP0992512B1 EP99307762A EP99307762A EP0992512B1 EP 0992512 B1 EP0992512 B1 EP 0992512B1 EP 99307762 A EP99307762 A EP 99307762A EP 99307762 A EP99307762 A EP 99307762A EP 0992512 B1 EP0992512 B1 EP 0992512B1
Authority
EP
European Patent Office
Prior art keywords
cortisol
conjugate
labeled
bound
reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99307762A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0992512A2 (en
EP0992512A3 (en
Inventor
Harold C. Warren
Brian A. Snyder
Lisa D. Sprague
Shirley Y. Lynn
Paul B. Contestable
Holly L. Groth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Clinical Diagnostics Inc
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22291927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0992512(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of EP0992512A2 publication Critical patent/EP0992512A2/en
Publication of EP0992512A3 publication Critical patent/EP0992512A3/en
Application granted granted Critical
Publication of EP0992512B1 publication Critical patent/EP0992512B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones

Definitions

  • the present invention relates to haptens and conjugate labels having improved specificity for anti-cortisol antibodies, methods for their preparation and use in immunoassays for the detection of cortisol. More particularly, the present invention relates to conjugates comprising horseradish peroxidase and reduced cortisol.
  • Cortisol is the major glucocorticoid in humans. It is synthesized and secreted by the zona fasciculata and the zona reticularis of the adrenal cortex. It is involved in the regulation of carbohydrate, protein, and lipid metabolism. Cortisol levels can rise ten fold following surgery or other major trauma, as the steroid acts to prevent vascular collapse, reduce inflammation, and suppress the immune system.
  • Cushing's syndrome is the term used to describe any condition resulting from an increased concentration of circulating glucocorticoid, usually cortisol ( Clinical Chemistry: Theory, Analysis, and Correlation; Lawrence A. Kaplan, Amadeo J. Pesce, CV Mosby Company, 1989, pp 673-4).
  • cortisol detection and quantification of cortisol in human serum, plasma or urine is required for proper diagnosis, treatment and follow-up of cortisol related conditions.
  • cortisol The sensitivity and specificity of an immunoassay for cortisol are dependent on the labeled cortisol. It is important that labeled cortisol effectively compete for the limited number of anti-cortisol binding sites with steroids structurally similar to cortisol that may be present in a sample. Otherwise, a clinically acceptable determination of the amount of cortisol in the sample will not be obtained.
  • 11-deoxycortisol which is structurally similar to cortisol ( Fundamentals of Clinical Chemistry, Tietz,N.W., W.B.Saunders Co., 1987,p 569) and potentially can compete with labeled cortisol for binding to anti-cortisol antibody.
  • cortisol-like steroids that may be present in a sample, which potentially can compete with labeled cortisol for anti-cortisol antibody, include prednisolone, cortisone, and corticosterone. Such competition with labeled cortisol for anti-cortisol antibody is termed cross-reactivity.
  • cortisol assays can exhibit cross-reactivity with all the above-identified steroids. For example, a cross-reactivity with 11-deoxycortisol of greater than 10 percent has been observed; seriously compromising the accuracy of the assay for cortisol.
  • Aquaculture 117, p351-63 (1993) discloses 3-carboxy methyloxine linked cortisol conjugates for use in raising antibodies and in immunoassays.
  • the present invention relates to compositions comprising novel reduced cortisol conjugates, methods for their preparation and use in immunoassays for cortisol.
  • it relates to conjugates of reduced cortisol as immunogens or haptens for eliciting anti-cortisol or anti-reduced cortisol antibodies.
  • labeled reduced cortisol conjugates of the present invention effectively compete with cortisol-like steroids for binding to anti-cortisol antibodies, thereby exhibiting significantly less cross-reactivity compared with prior art labeled cortisol conjugates.
  • Immunoassays for cortisol comprising labeled reduced cortisol conjugates of the present invention exhibit both improved specificity and sensitivity for the determination of cortisol.
  • the present invention provides a reduced cortisol conjugate of formulae IA, IB and ID, which may be produced via compounds of formula IC.
  • X is O, S, sufonyl, or phosphono
  • X 1 is a labeled or unlabeled natural or synthetic polymer or a label
  • Y 1 is a linking group or a bond
  • X 2 is a labeled or unlabeled natural or synthetic polymer or a label
  • Y 2 is a linking group or a bond
  • a 1 and A 2 are each hydrogen or A 1 and A 2 together form a single bond
  • B 1 and B 2 are each hydrogen or B 1 and B 2 together form a single bond
  • E 1 and E 2 are each hydrogen or E 1 and E 2 together form a single bond provided at least one of A 1 and A 2 , or B 1 and B 2 , or E 1 and E 2 are each hydrogen.
  • the present invention relates to methods for the preparation of reduced cortisol conjugates. Accordingly, we provide a method for preparing a reduced cortisol conjugate of formulae : or wherein X, X 1 , Y 1 , X 2 , Y 2 , A 1 , A 2 , B 1 , B 2 , E 1 and E 2 are as defined above, comprising:
  • the present invention relates to methods for the qualitative or quantitative determination of cortisol that utilize the novel labeled reduced cortisol conjugates.
  • the assay method described above may be combined with a step wherein the labeled reduced cortisol conjugate that is bound is separated from the labeled reduced cortisol conjugate that is not bound to the immobilized or immobilizable receptor;
  • the present invention relates to haptens or immunogens of formula IA, IB, IC or ID as defined above and compositions comprising the immunogens. It also relates to methods of producing anti-cortisol antibodies using the immunogens of the present invention, by immunizing a host animal, removing blood from the host, and separating antibodies that bind cortisol from the host animal's blood serum or plasma. In another related method, the spleen, thymus or other organ that is populated with antibody producing cells is removed from the immunized host animal, antibody secreting hybridomas are prepared using antibody producing cells of the spleen, thymus or other organ so removed, and antibodies that bind cortisol are selected therefrom.
  • the present invention relates to methods of reducing cross-reactivity in immunoassays for cortisol using labeled reduced cortisol conjugates of formula IA, IB, IC or ID.
  • the labeled reduced cortisol conjugates of the present invention effectively compete with cortisol-like steroids for binding to anti-cortisol antibodies, thereby exhibiting significantly less cross-reactivity compared with prior art labeled cortisol conjugates.
  • a "natural polymer” for the purpose of the present invention is herein defined as one that originates from a biological source including but not limited to: microorganisms, fungi, viruses, human, cow, pig, mouse, cat, dog, rat, or insect.
  • Such natural polymers include proteins, peptides, glycoproteins, lipoproteins and recombinant and chemically modified species thereof, polysaccharides, celluloses, collagens, and latexes.
  • Somewhat more specific examples include, dextrans, porcine, human, mouse, rat and bovine serum albumins or globulins, strepavidin, antibodies, enzymes such as peroxidase, ⁇ -galactosidase, and alkaline phosphatase.
  • a "synthetic polymer” is defined herein as a polymer that does not necessarily directly originate from a biological source. It is one that is prepared by methods well known to the skilled artisan. For example, by way of monomer condensation using emulsion polymerization, ionic chain polymerization, carbonyl polymerization, radical chain polymerization and the like.
  • It includes homopolymers such as polyacrylamides, polymethacrylates, polystyrenes, substitited polyacrylamides, polymethacrylates, and polystyrenes, and copolymers comprising two or more different monomeric units, such as acrylamide or substituted acrylamide, styrene and substituted styrene, and the like, as would be well known to one skilled in the art. It includes blockcopolymers, graftcopolymers, aqueous soluble and aqueous insoluble polymers and covalent and non-covalent combinations with natural polymers.
  • label includes: chemical elements, compounds, and enzymes that are capable of being detected directly or indirectly using, for example, absorption, fluorescence, or reflectance spectrophotometry, or radiation detection methods.
  • a label may be a natural or synthetic polymer.
  • horseradish peroxidase is both a label and a natural polymer. But a label is not necessarily a natural or synthetic polymer.
  • a label capable of direct detection is one that is intrinsically capable of producing a detectable signal.
  • Such labels include organic and inorganic substances capable of fluorscence, or phosphoresence, such as but not limited to fluorescein, and derivatives thereof, and N-(3-fluoranthyl)-maleimide, radionucleides, such as carbon 14, tritium and phosporus 32, and the like. Included are substances having appropriate spectral absorption such as but not limited to, azo-oxo, azo-tetrazo, azine, oxazine, thiazine, quinoline, indamine, pyrone and pyrazolone dyes.
  • a label that is capable of indirect detection requires the presence of one or more additional substances for production of the detectable signal.
  • labels typically include but are not limited to enzymes that require the presence of a substrate(s), cofactor(s), metal(s) and the like.
  • Peroxidases most particularly, horseradish peroxidase, a common label, requires an electron donor and an oxidizing agent, such as luminol, di- or triarylimidazole leucodyes and hydrogen peroxide to produce a chemiluminescent product or dye, respectively.
  • Other enzymes such as ⁇ -galactosidase, glucose oxidase and alkaline phosphatase, and the like, are also contemplated.
  • labels include radioactive tags, enzymes, chromophores, fluorophores, stable free radicals, and enzyme cofactors, inhibitors and allosteric effectors.
  • a “reducing agent”, for the purpose of the present invention, is any compound or reagent admixture that is capable of hydrogenating a double bond, such as carbon-carbon, carbon-nitrogen, carbon-oxygen and carbon-sulfur double bonds.
  • Useful reducing agents include but are not limited to: aluminum hydride, lithium aluminum hydride, borohydride and salts thereof. Catalytic hydrogenation over paladium, platinum or nickel or other hydrogenation methods can also be used. Sodium borohydride is a preferred reducing agent.
  • a “linking group” is defined herein, as a chemical group comprising one or more atoms.
  • a linking group connects one molecule to another, such as a natural polymer to a natural polymer, a synthetic polymer to a synthetic polymer, a natural polymer to a synthetic polymer, a label to a natural or synthetic polymer, a label to reduced cortisol, a label to cortisol, and so on, through formation of a covalent bond with each of the molecules it joins.
  • the linking group can comprise a substituted or unsubstituted straight chain or branched alkyl or heteroalkyl, such as oxyalkyl, thioalkyl, aminoalkyl, substituted or unsubstituted alkenyl, one or more substituted or unsubstituted hydrocarbon heterocyclic rings, one or more substituted or unsubstituted aryl or heteroaryl rings such as but not limited to, imidazoyl, isoxazolyl, pyridyl, piperidyl, piperazinyl, pyrazolyl,triazolyl, oxadiazolyl, pyridazinyl, pyrimidyl, pyrazinyl, quinolinyl, and quinazolinyl.
  • a substituted or unsubstituted straight chain or branched alkyl or heteroalkyl such as oxyalkyl, thioalkyl, aminoalkyl, substituted or unsubstitute
  • linking or coupling of macromolecules, such as natural and synthetic polymers to other macromolecules, or linking small molecules, such as cortisol or analogs of cortisol, to macromolecules is well known in the art.
  • carbon 3(C3) is reactive with nucleophiles including, amines, oximes, and thio-oximes and others known in the art.
  • the nucleophilic species may be a coupling (linking) agent, a label, a natural or synthetic polymer. If it is a coupling agent or other species having a reactive functional group (a label, etc.), upon covalently bonding to the C3 of cortisol it may be reacted further with another coupling agent or other species having an appropriately reactive functional group.
  • Cortisol so derivatized can be used as the starting point for preparing the reduced cortisol compounds of the instant invention.
  • Details of coupling chemistry and linking groups may be found in numerous publications, including, US Patents 3,654,090; 3,791,932; 3,875,011; 4,016,043; 4,040,907; 4,092,479; 4,213,894; 4,243,749; 4,376,165; 4,410,643; 4,752,658; 4,828,978; 4,879,249; 4,997,772; 5,053,497; 5,106,732; 5,147,777; 5,155,166; 5,162,219; 5,177,023; 5,284,948; 5,298,403; 5,308,749; 5,374,516; 5,391,483; 5,397,695; 5,401,633; 5,527,709; 5,543,311; 5,578,457; 5,652,346; 5,763,588; 5,770,390 and references identified
  • a linking group and molecule to which it is covalently attached can be connected through amide, ester, ether, thioester, and disulfide bonds.
  • coupling or linking chemistry that includes reacting the molecules to be coupled with condensing agents such as carbodiimides, maleimides, ethylchloroformate, and glutaraldehyde is well known in the art.
  • sample refers to any substance that may contain the analyte of interest.
  • a sample can be a biological fluid, such as cerebral spinal fluid, semen, vaginal secretions, sputum, ascites fluid, lacrimal fluid, sweat, serum, plasma, urine, whole blood or whole blood components including red and white blood cells, platelets, and other fluids or tissues of the body that may contain the analyte of interest.
  • samples may be obtained from water, soil and plants.
  • Immunoassays which take advantage of natural immunological reactions, have found wide-spread use as analytical techniques in clinical chemistry. Because of the specificity of the reactions, they are particularly advantageous in quantifying biological analytes, that are present in very low concentration in biological fluids.
  • biological analytes include, for example, antibodies, therapeutic drugs, narcotics, enzymes, hormones, proteins, etc.
  • a labeled analyte (the term includes immunocompetent analogs of the analyte) is placed in competition with unlabeled analyte for reaction with a fixed amount of an appropriate receptor, which is often immobilized on a solid susbstrate, or is capable of immobilization thereto.
  • the labeled analyte that is bound to the receptor is separated from free labeled analyte. Unknown concentrations of the analyte can be determined from the measured signal of either the bound or free labeled analyte.
  • the reaction proceeds as follows: Analyte + labeled analyte + receptor ⁇ analyte-receptor + labeled analyte-receptor.
  • Immunoassays can be carried out in solution, in test devices where soluble and insoluble components can be separated, or in dry analytical elements. Immunoassays can be heterogeneous or homogeneous as these terms are known in the art. In heterogeneous assays, bound and free labeled immunoreactants (labeled analyte or labeled receptor for an analyte)are separated prior to signal measurement; whereas, in homogeneous assays separation of free from bound labeled immunoreactant is not required.
  • the reduced cortisol conjugates of the instant invention can used in both homogeneous and heterogeneous assays.
  • analyte and sample containing free analyte can be added simultaneously or separately to an admixture comprising immobilized or immobilizable receptor that binds the analyte.
  • labeled analyte and immobilized receptor when present together in the element prior to contact with sample, are preferably present in separate zones.
  • HRP horseradish peroxidase
  • any or all of these sites can be reduced by treatment with a reducing agent or reducing admixture that is capable of hydrogenating a double bond, yielding products having a single site reduced as in the structures shown below. as well as, compounds having any two of the sites reduced, yielding three different reduced species, and all three sites reduced, as is readily apparent to the skilled artisan.
  • Other conjugates comprising cortisol which upon reduction produce the compounds generically defined in structures 1A, 1B, 1C and 1D, analogously will form different reduced cortisol species as exemplified above with Cortisol-3-CMO-BSA.
  • Bovine Serum Albumin (Cortisol-3-CMO-BSA) was prepared as described below. Alternatively, it can be purchased from Sigma Chemical Co., St. Louis, Missouri.
  • a stock solution of N-hydroxysuccimide (NHS) was prepared by dissolving 20mg of NHS in 3.0 mL of dioxane.
  • a stock solution of dicyclohexylcarbodiimide (DCC) was also prepared by dissolving 30 mg of DCC in 2.50 ml of dioxane.
  • Bovine Serum Albumin BSA
  • 0.1M sodium hydrogen carbonate solution 12 mL of 0.1M sodium hydrogen carbonate solution.
  • the solution was mixed until clear and at the end of the three hour incubation, 3.0ml of the activated Cortisol-3-CMO was added to the BSA solution.
  • the mixture was stirred and incubated at ambient temperature for two hours.
  • 15 mL of 0.1M sodium phosphate, 0.3M sodium chloride (pH 6.0) buffer was added.
  • the mixture was filtered through a 5.0um and 0.45um Sartorius Minisarts and then cromatographed on a 5 X 70 cm Superdex 200PG column at a flow rate of 8.0 mL/min.
  • the first tube corresponding to the major peak and the following ten (one minute) fractions were collected and pooled. Pool the fractions. The pooled fractions were dialyzed against water for approximately fifteen hours. The dialysis was repeated . The dialysate was filtered through a 0.2 um Sartorius Minsart and lyophilized in small aliquots and kept frozen until needed.
  • Cortisol-3-CMO-BSA (24 mg) was dissolved in 4 mL of a solution of 50 mM sodium carbonate and 100 mM sodium chloride at pH 9.5. An aliquot, 0.60 mL, of an aqueous solution of sodium borohydride (4 mg per mL) was added to the cortisol-3-CMO-BSA solution, which was then mixed continuously for thirty minutes at 20° C. The pH was then adjusted, using about 200 ⁇ L of a 0.5 M sodium phosphate solution, to a value in a range between pH 7.2 to 7.5 to decompose any excess borohydride. The solution was gently mixed until effervescence ceased and allowed to stand for about fifteen minutes.
  • the reaction mixture was then filtered through a 0.45 ⁇ filter and chromatographed on a Sephadex G25 1.6 X 14.5 cm column pre-equilibrated with 0.02 M phosphate, pH 7.0, at a flow rate of about 40 mL/hr.
  • the fraction size collected was about 0.67 mL (1 min). Fifteen of the most concentrated fractions, that is, those fractions having a large absorption at 280 nm were pooled.
  • SMCC Succinimidyl 4- (N-maleimidomethyl) cyclohexane-1-carboxylate
  • DMF N,N-dimethylformamide
  • the quenched reaction mixture was then chromatographed on a 3.2 X 10 cm column filled with Sephadex G25 pre-equilibrated with a solution of 0.1 M phosphate and 5 mM ethylenediaminetetraacetic acid (EDTA), pH 6.0, at a flow rate of about 161 mL/hr.
  • EDTA ethylenediaminetetraacetic acid
  • One milliliter fractions were collected. Eight of the most concentrated fractions (having a large absorption at 280 nm) were pooled and used for conjugation to activated HRP.
  • Horseradish peroxidase was dissolved in 0.1 M phosphate, pH 7.5, at a final HRP concentration of 10 mg/mL. Five milliliters of the HRP solution were transferred to a 20 mL reaction vial. A 0.5 mL aliquot of S-acetylthioacetic acid, N-hydroxysuccinimidyl ester (SATA) in DMF (25 mg/mL) was added to the reaction vial containing the HRP solution. The solution was mixed gently then incubated at 20°C for sixty minutes.
  • SATA S-acetylthioacetic acid, N-hydroxysuccinimidyl ester
  • the activated, reduced cortisol-3-CMO-BSA 21.47 mL was combined with 11.55 mL of activated HRP.
  • the solution was mixed gently, and incubated at 20°C for twenty hours.
  • An aliquot (224 ⁇ L) of a solution containing mercaptoethanol in water (1 percent of the thiol by volume) was added to the reaction mixture and the solution was mixed gently and allowed to stand for about 15 minutes.
  • a 476 ⁇ L aliquot of a solution containing 10 mg/mL N-ethylmaleimide in DMF was then added to the reaction mixture, and incubated an additional twenty minutes after mixing.
  • reaction mixture was then chromatographed on a 4.4 X 50 cm column containing Superdex 200 pre-equilibrated with a solution of 0.1 M phosphate and 0.3 M NaCl at pH 6.0 using a flow rate of about 344 mL per hour. One minute fractions were collected. Twenty six of the most concentrated fractions centered around the first eluates having a maximum absorption at 280 nm were pooled.
  • the absorption of the conjugate pool (cj)and the HRP solution (in Example 2 above, prior to activation and sufficiently diluted in phosphate buffer to obtain an accurate absorption measurement) were determined at 280nm and 403nm, A 403 cj, A 280 cj and A 403 HRP, A 280 HRP respectively.
  • HRP-RC conjugate Evaluation of the HRP labeled reduced cortisol-3-CMO-BSA (hereinafter referred to as HRP-RC conjugate) was evaluated using an Ortho-Clinical Diagnostic VITROS ECi chemiluminesence-based assay methodology.
  • the above method was used to determine the concentration of potential cross reactant (steroid that is structurally similar to cortisol: 11-deoxycortisol, prednisolone, corticosterone and cortisone) that displaced fifty percent of a fixed amount of a comparative HRP labeled cortisol conjugate (nonreduced cortisol, HRP-NRC) or HRP-RC conjugate bound to a fixed amount of anti-cortisol antibody.
  • potential cross reactant steroid that is structurally similar to cortisol: 11-deoxycortisol, prednisolone, corticosterone and cortisone
  • Varied levels of the potential cross reactant were added to sample containers containing either the comparative labeled cortisol conjugate (nonreduced cortisol, HRP-NRC) or HRP-RC conjugate of the instant invention, as described above.
  • Percent cross-reactivity is defined as The concentration of cortisol that displaced 50% of the HRP-NRC comparative conjugate (or the HRP-RC conjugate) divided by the concentration of cross-reactant that displaced 50% of the HRP-NRC comparative conjugate (or the HRP-RC conjugate) multiplied by 100 as determined per the assay method described hereinabove.
  • Percent Cross-Reactivity Compound HRP-NRC Comparative Label HRP-RC Invention Label cortisol 100 100 prednisolone 34.8 24.6 11-deoxycortisol 28.4 2.2 cortisone 5.5 1.8 corticosterone 4.4 3.3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP99307762A 1998-10-02 1999-10-01 Reduced cortisol conjugate Expired - Lifetime EP0992512B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10283698P 1998-10-02 1998-10-02
US102836P 1998-10-02

Publications (3)

Publication Number Publication Date
EP0992512A2 EP0992512A2 (en) 2000-04-12
EP0992512A3 EP0992512A3 (en) 2002-04-17
EP0992512B1 true EP0992512B1 (en) 2005-12-14

Family

ID=22291927

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99307762A Expired - Lifetime EP0992512B1 (en) 1998-10-02 1999-10-01 Reduced cortisol conjugate

Country Status (8)

Country Link
US (1) US6383766B1 (enExample)
EP (1) EP0992512B1 (enExample)
JP (2) JP2000143691A (enExample)
AT (1) ATE312842T1 (enExample)
CA (1) CA2283597C (enExample)
DE (1) DE69928888T2 (enExample)
DK (1) DK0992512T3 (enExample)
ES (1) ES2253866T3 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
JP2004063363A (ja) * 2002-07-31 2004-02-26 Semiconductor Energy Lab Co Ltd 電界発光素子用材料、およびそれを用いた電界発光素子
DE102004034008A1 (de) * 2004-07-14 2006-02-09 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Corticoid-Konjugaten
GB2418665B8 (en) * 2004-10-04 2008-03-25 Biotrin Intellectual Pty Ltd Stabilising diluent for a protein-horseradish peroxidase conjugate
CN104251903A (zh) * 2007-11-22 2014-12-31 特拉斯医药有限公司 血液试样的品质评估方法
JP2017150815A (ja) * 2014-05-29 2017-08-31 株式会社日立製作所 臨床検査キット及び化学物質検出方法
JP7579190B2 (ja) * 2020-03-30 2024-11-07 ミナリスメディカル株式会社 競合法による検体中のステロイドホルモンの測定用キットの安定化方法
CN119306830B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗皮质醇抗体、检测皮质醇的试剂和试剂盒

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992158A (en) 1973-08-16 1976-11-16 Eastman Kodak Company Integral analytical element
US3867258A (en) 1973-11-08 1975-02-18 American Cyanamid Co Lactate dehydrogenase test material
CA1054034A (en) 1975-06-20 1979-05-08 Barbara J. Bruschi Multilayer analytical element
US4042435A (en) 1976-01-05 1977-08-16 The Goodyear Tire & Rubber Company Closed torus wound carcass for a closed torus tire
US4050898A (en) 1976-04-26 1977-09-27 Eastman Kodak Company Integral analytical element
US4081525A (en) * 1976-08-16 1978-03-28 Beckman Instruments, Inc. Radioimmunoassay of plasma steroids
US4128629A (en) * 1977-07-05 1978-12-05 Corning Glass Works Extraction-free cortisol assay
US4153668A (en) 1978-01-03 1979-05-08 Eastman Kodak Company Multi-zone analytical element and method using same
IL56467A (en) * 1978-02-10 1982-04-30 Sin Hang Lee Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues
US4258001A (en) 1978-12-27 1981-03-24 Eastman Kodak Company Element, structure and method for the analysis or transport of liquids
JPS55164356A (en) 1979-06-08 1980-12-22 Fuji Photo Film Co Ltd Multi-layer analysis sheet for liquid sample analysis
JPS5634700A (en) * 1979-08-29 1981-04-06 Teikoku Hormone Mfg Co Ltd Novel tetrahydrocorticosteroid derivative and antiserum
US4372745A (en) 1979-12-19 1983-02-08 Electro-Nucleonics, Inc. Chemical luminescence amplification substrate system for immunochemistry involving microencapsulated fluorescer
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS57101761A (en) 1980-12-17 1982-06-24 Konishiroku Photo Ind Co Ltd Analyzing element
US4483921A (en) 1981-01-12 1984-11-20 Collaborative Research, Inc. Immunoassay with antigen or antibody labeled liposomes sequestering enzyme
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
DE3380125D1 (en) 1982-03-22 1989-08-03 Amersham Int Plc Assay for the free portion of substances in biological fluids
US5599720A (en) * 1982-08-27 1997-02-04 Multilyte Limited Measurement of analyte concentration
US4510251A (en) * 1982-11-08 1985-04-09 Abbott Laboratories Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers
JPS6020149A (ja) * 1983-07-15 1985-02-01 Teikoku Hormone Mfg Co Ltd 免疫化学的測定方法及びその試薬
US4847080A (en) 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
DE3662730D1 (en) 1985-01-24 1989-05-11 Inst Int Pathologie Cellulaire Immunoassay method for antibodies of different classes in a liquid sample
JPS61272661A (ja) 1985-05-29 1986-12-02 Hitachi Ltd イムノアツセイ法
EP0204523B1 (en) 1985-05-31 1992-02-26 Syntex (U.S.A.) Inc. Glucose-6-phosphate dehydrogenase conjugates, their preparation and use
US4859610A (en) 1985-06-05 1989-08-22 Synbiotics Corporation Immunoassay incubation device
US4855226A (en) 1985-06-07 1989-08-08 Beckman Instruments, Inc. Novel competitive assay for theophylline and reagent for use therein
US4670381A (en) 1985-07-19 1987-06-02 Eastman Kodak Company Heterogeneous immunoassay utilizing horizontal separation in an analytical element
JP2591738B2 (ja) 1985-08-21 1997-03-19 ベーリンガー マンヘイム コーポレイション 特異的結合アッセイにおける成分の分離，混合および検出のための方法および装置
US4868106A (en) 1985-10-17 1989-09-19 Konishiroku Photo Industry Co., Ltd. Analytical element and method for determining a component in a test sample
JPS62119457A (ja) * 1985-11-19 1987-05-30 Sapporo Imuno Diagnostic Lab:Kk 先天性副腎皮質過形成のマススクリ−ニング用診断薬キツト
US4822747A (en) 1986-12-09 1989-04-18 Miles Inc. Polyacrylamide gel particles having hapten moieties bound thereto as immunoassay reagent
US4863876A (en) 1987-01-15 1989-09-05 Hevey Richard C Method of detecting and quantifying ligands in liquids via biotin-avidin-medicated fluorescence polarization
US4847194A (en) 1987-03-13 1989-07-11 Becton, Dickinson And Company Colorimetric detection of delta-5-3-ketosteroid isomerase and immunoassay based thereon
US4857453A (en) 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
US4857454A (en) 1987-04-09 1989-08-15 a Division of Yeshiva University Albert Einstein College of Medicine of Yeshiva University Spectrophotometric method for kinetic absorbance measurements in two-phase enzyme immunoassay and apparatus therefor
US4950592A (en) 1987-05-12 1990-08-21 Eastman Kodak Company Blend of monoclonal antibodies
US4853335A (en) 1987-09-28 1989-08-01 Olsen Duane A Colloidal gold particle concentration immunoassay
AU3359493A (en) * 1992-01-17 1993-08-03 Selective Antibodies Limited Determination of haptens
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5650324A (en) 1994-05-31 1997-07-22 Johnson & Johnson Clinical Diagnostics, Inc. Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase
US5663054A (en) 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay
US5912114A (en) * 1997-09-12 1999-06-15 Johnson & Johnson Medical, Inc. Wound diagnosis by quantitating cortisol in wound fluids

Also Published As

Publication number Publication date
DE69928888D1 (de) 2006-01-19
DK0992512T3 (da) 2008-03-03
JP2000143691A (ja) 2000-05-26
HK1027111A1 (en) 2001-01-05
EP0992512A2 (en) 2000-04-12
CA2283597C (en) 2008-02-05
JP2011148821A (ja) 2011-08-04
CA2283597A1 (en) 2000-04-02
ES2253866T3 (es) 2006-06-01
US6383766B1 (en) 2002-05-07
EP0992512A3 (en) 2002-04-17
ATE312842T1 (de) 2005-12-15
DE69928888T2 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
US4469797A (en) Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
JP2011148821A (ja) 還元型コルチゾール接合体
US11377483B2 (en) Sandwich assay design for small molecules
DE3853940T2 (de) Vaginale Probe, Test und Reagenzien.
US11913965B2 (en) Sandwich assay for small molecules
US5830672A (en) Elisa kit for the rapid determination of N-acetyltransferase (NAT2) phenotypes
EP2823304B1 (en) Sandwich assay for immunosuppressant drugs
JPS6345561A (ja) ポリアルキレングリコール架橋基を有する酵素標識抗体試薬
US20170153254A1 (en) Assays for vitamin d epimers
DE3018593A1 (de) Verfahren zur quantitativen bestimmung von cyclischen nucleotiden
DK172410B1 (da) Histaminderivat, histamin-immunogen-konjugat samt antistof fremstillet mod konjugatet
CA1093962A (en) Bile acid competitive assay using protein binding inhibitor
US20170362579A1 (en) Conjugates for assays for oxycodone and oxymorphone
HK1027111B (en) Reduced cortisol conjugate
EP0957364A2 (en) Dye-labeled protein conjugate and method for preparing the same
WO1990011526A1 (en) Cancer diagnosis
JPH0786507B2 (ja) リガンドの測定方法
DE19856777B4 (de) Anti-Petasin-Antikörper, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0957362A2 (en) Dye-labeled protein conjugate and method for preparing the same
US20140212987A1 (en) Signal Ratio in Assay Calibrators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20020923

AKX Designation fees paid

Free format text: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031013

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051214

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69928888

Country of ref document: DE

Date of ref document: 20060119

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060314

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060314

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060515

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2253866

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1027111

Country of ref document: HK

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20061011

Year of fee payment: 8

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061031

26N No opposition filed

Effective date: 20060915

NLXE Nl: other communications concerning ep-patents (part 3 heading xe)

Free format text: A REQUEST FOR RESTORATION TO THE PRIOR STATE (ARTICLE 23 OF THE PATENTS ACT 1995) HAS BEEN FILED ON 20061229

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

Ref country code: CH

Ref legal event code: AEN

Free format text: DAS PATENT IST AM 07.03.2007 GESTUETZT AUF DAS AM 28.12.2006 EINGEREICHTE WIEDEREINSETZUNGSGESUCH AUF GRUND VON ART. 47 PATG WIEDER IN KRAFT GESETZT W

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

NLXE Nl: other communications concerning ep-patents (part 3 heading xe)

Free format text: THE REQUEST FOR RESTORATION TO THE PRIOR STATE AS PROVIDED FOR IN ARTICLE 23 OF THE PATENTS ACT 1995 (SEE PUBLICATION IN HEADING XE OF THE PATENT BULLETIN OF 20070301/03 HAS BEEN GRANTED; THE RESTORATION OF THE PATENT HAS BEEN ENTERED IN THE PATENT REGISTER

REG Reference to a national code

Ref country code: DK

Ref legal event code: EGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061001

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: SE

Effective date: 20070404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20101009

Year of fee payment: 12

Ref country code: DK

Payment date: 20101014

Year of fee payment: 12

Ref country code: AT

Payment date: 20101014

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20101016

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20101122

Year of fee payment: 12

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120501

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111031

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 312842

Country of ref document: AT

Kind code of ref document: T

Effective date: 20111001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111001

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111002

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20151012

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161031

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161031

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170918

Year of fee payment: 19

Ref country code: GB

Payment date: 20170927

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170927

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20171011

Year of fee payment: 19

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69928888

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20181001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181002

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181001